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Abstract: Background: The aim of this review was to evaluate the adjunctive effect of autologous
platelet concentrates (APCs) for the treatment of furcation defects, in terms of scientific quality
of the clinical trials and regeneration parameters assessment. Methods: A systematic search was
carried out in the electronic databases MEDLINE, SCOPUS, CENTRAL (Cochrane Central Register of
Controlled Trials), and EMBASE, together with hand searching of relevant journals. Two independent
reviewers screened the articles yielded in the initial search and retrieved the full-text version of
potentially eligible studies. Relevant data and outcomes were extracted from the included studies.
Risk of bias assessment was also carried out. The outcome variables, relative to baseline and
post-operative defect characteristics (probing pocket depth (PPD), horizontal and vertical clinical
attachment loss (HCAL, VCAL), horizontal and vertical furcation depth (HFD, VFD) were considered
for meta-analysis. Results: Ten randomized trials were included in this review. Only one study
was judged at high risk of bias, while seven had a low risk, testifying to the good level of the
evidence of this review. The meta-analysis showed a favorable effect regarding all outcome variables,
for APCs used in adjunct to open flap debridement (p < 0.001). Regarding APCs in adjunct to bone
grafting, a significant advantage was found only for HCAL (p < 0.001, mean difference 0.74, 95% CI
0.54, 0.94). The sub-group analysis showed that both platelet-rich fibrin and platelet-rich plasma in
adjunct with open flap debridement, yielded significantly favorable results. No meta-analysis was
performed for APCs in combination with guided tissue regeneration (GTR) as only one study was
found. Conclusion: For the treatment of furcation defects APCs may be beneficial as an adjunct to
open flap debridement alone and bone grafting, while limited evidence of an effect of APCs when
used in combination with GTR was found.
Keywords: autologous platelet concentrates; bone defects; bone grafting; bone regeneration; furcation
defects; periodontal defects; periodontal regeneration; periodontal surgery; platelet-rich plasma;
platelet-rich fibrin; plasma rich in growth factors; tissue healing
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1. Introduction
Furcation involvement is defined as bone resorption and attachment loss in the inter-radicular
space that results from plaque associated periodontal disease [1]. The treatment of periodontal disease
associated with furcation represents a challenge for the clinician, due to the complexity in anatomy
and morphology of such area. The unfavorable anatomic feature of the furcation restricts adequate
instrumentation for proper debridement, thereby limiting the prognosis of the involved teeth [2].
Various treatment modalities, including surgical and non-surgical therapy, have been proposed to
improve the prognosis based on the degree of furcation involvement. Several classifications have been
proposed over the years (Table 1), based either on the severity of horizontal probing depth into the
furcation defect or on the vertical amount of alveolar bone loss within the defect [3]. The most popular
one was developed by Glickman, which divides furcation defects into four grades [4]. Non-surgical
strategies such as scaling and root planing, furcation-plasty, etc. are employed to treat the furcations
with Grade I initial involvement which restores the gingival health. Conversely, surgical procedures
including regenerative and resective approaches, are performed for the treatment of more advanced
lesions, to allow access to the internal complex areas of furcations. The traditional resective approach
may negatively affect the long term prognosis of the treated teeth, however, it is considered as the
treatment of choice for grade III and IV furcation lesions, aiming at facilitating maintenance of the
furcation area.
Regenerative approaches are aimed at furcation closure by the formation of new bone, cementum
and periodontal ligament in the involved inter-radicular space. Thorough debridement with adequate
instrumentation following surgical exposure of furcation involved area, is one of the earliest and
most well-documented treatment protocols to achieve regeneration in grade II furcation lesions [5].
In addition, various studies were carried out in the recent past, using bone substitutes, barrier
membrane, autologous, and recombinant growth factors in order to provide evidence of improved
bone fill and attachment gain in treating grade II furcation lesions [6,7].
The use of biologic agents consisting of growth and differentiation factors like rhBMP2
(recombinant human bone morphogenetic protein-2), rhPDGF (recombinant human platelet-derived
growth factor), and TGF-β (transforming growth factor beta), had proven to promote osteogenic
induction in cases of furcation treatment, in animal studies [8–10]. Additionally, the use of autologous
platelet concentrates (APCs) is gaining popularity as a source of multiple growth factors in high
concentrations, for regenerative treatments in many clinical applications. The contribution of
blood-derived platelets to the bone healing process is mainly based on the growth factors stored
in their granules and released upon activation. Autologous platelet concentrates are advantageously
used as a cost-effective adjunct to surgical regenerative therapy, even in combination with bone grafts
and barrier membranes. Several randomized controlled trials have reported on the efficacy of the use of
these APCs when used alone or in combination with various regenerative strategies and other biologic
agents, suggesting improvement of post-operative soft and hard tissue healing, and improved bone fill
and attachment gain [6,11–17]. Different types of APCs are available, each with peculiar features, the
most popular being platelet-rich plasma (PRP), along with platelet-rich fibrin (PRF), plasma rich in
growth factors (PRGF) and concentrated growth factors (CGF).
A recent systematic review and meta-analysis [18], evaluating the effect of use of platelet-rich
fibrin (PRF) in adjunct to open flap debridement, included two clinical trials in treatment of grade II
furcation with nine month follow-up and concluded favorable results with the use of PRF in terms of
clinical attachment level gain (mean difference 1.25 CI 95% [0.82, 1.65], p = 0.07) and bone fill (mean
difference 1.52 CI 95% [1.18, 1.87], p = 0.05). Another systematic review [19] included two split-mouth
clinical trials evaluating the effect of platelet-rich plasma and reported no consistent evidence regarding
the effect of PRP in treatment of furcation defects.
The aim of this systematic review is to evaluate the adjunctive effect of APCs in treatment of
furcation defects both qualitatively and quantitatively, in terms of scientific quality of the clinical trials
and regeneration parameters assessment.
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Table 1. Various proposed classification systems of furcation involvement.
Sl Author Year Classification System
Horizontal Component
1 Goldman, H.M [20] 1958
Grade I: Incipient lesion;
Grade II: Cul-de-sac lesion;
Grade III: Through-and-through lesion
2 Staffileno, H.J. [21] 1969
Class I: Furcations with a soft tissue lesion extending to furcal level but with a
minor degree of osseous destruction;
Class II: Furcations with a soft tissue lesion and a variable degree of osseous
destruction but not a through-and-through communication through the furca;
Class III: Furcations with osseous destruction with through-and-through
communication
3 Glickman, I. [4] 1972
Grade I: Incipient lesion. Suprabony pocket and slight bone loss in the
furcation area.
Grade II: Loss of interradicular bone and pocket formation but a portion of the
alveolar bone and periodontal ligament remain intact.
Grade III: Through-and-through lesion.
Grade IV: Through-and-through lesion with gingival recession, leading to a
clearly visible furcation area.
4 Hamp, S.E. et al. [22] 1975
Degree I: Horizontal attachment loss < 3 mm;
Degree II: Horizontal attachment loss > 3 mm not encompassing the width of
the furcation area;
Degree III: Horizontal through-and-through destruction of the periodontal
tissue in the furcation area.
5 Ramjford, S.P. et al. [23] 1979
Class I: Tissue destruction < 2 mm (1/3 of tooth width) into the furcation;
Class II: Tissue destruction > 2 mm (>1/3 of tooth width);
Class III: Through-and-through involvement.
6 Richietti, P.A. [24] 1982
Class I: 1 mm of horizontal invasion;
Class Ia. 1–2 mm of horizontal invasion;
Class II: 2–4 mm of horizontal invasion;
Class IIa. 4–6 mm of horizontal invasion;
Class III: >6 mm of horizontal invasion.
7 Grant, D.A. et al. [25] 1988
Class I: Involvement of the flute only;
Class II: Involvement partially under the roof;
Class III: Through-and-through loss.
8 Goldman, H.M. et al.[26] 1988
Degree I: Involves furcation entrance;
Degree II: Involvement extends under the roof of furcation;
Degree III: Through-and-through involvement.
9 Basaraba, N. [27] 1990
Class I: Initial furcation involvement;
Class II: Partial furcation involvement;
Class III: Communicating furcation involvement.
10 Nevins, M. et al. [28] 1998
Class I: Incipient or early loss of attachment;
Class II: A deeper invasion and loss of attachment that does not extend to a
complete invasion;
Class III: Complete loss of periodontium extending from buccal to lingual
surface. Diagnosed radiographically and clinically
11 Walter, C.et al [29] 2009
Modification of the Hamp et al. classification.
Degree I: Horizontal attachment loss < 1/3 of the width of the tooth;
Degree II: Horizontal loss of support > 3 mm, < 6 mm;
Degree II–III: Horizontal loss of support > 6 mm, but not extending completely.
Degree III: Horizontal through-and-through destruction.
12 Carnevale, G. et al. [30] 2012
Degree I: Horizontal attachment loss < 1/3;
Degree II: Horizontal attachment loss > 1/3;
Degree III: Horizontal through-and-through destruction.
Vertical Component
1 Tal, H. et al. [31] 1982
Furcal rating 1: Depth of the furcation is 0 mm;
Furcal rating 2: Depth of the furcation is 1–2 mm;
Furcal rating 3: Depth of the furcation is 3 mm;
Furcal rating 4: Depth of the furcation is 4 mm or more.
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Table 1. Cont.
Sl Author Year Classification System
2 Eskow, R.N. et al. [32] 1984
Furcation involvement grade 1 is classified as:
Subclass A: Vertical destruction > 1/3;
Subclass B: Vertical destruction of 2/3;
Subclass C: Vertical destruction beyond the apical third of interradicular
height.
3 Tarnow, D. et al. [33] 1985
For each class of horizontal classification (I–III), a subclass based on the vertical
bone resorption was added: Subclass A: 0–3 mm; Subclass B: 4–6 mm; Subclass
C: >7 mm.
Horizontal & Vertical Component (Combined)
1 Easley, J.R. et al. [34] 1969
Class I: Incipient involvement, but there is no horizontal component to the
furca;
Class II: Type 1. Horizontal attachment loss into the furcation;
Type 2. Vertical attachment loss into the furcation;
Class III: Through-and-through attachment loss into the furcation;
Type 1. Horizontal attachment loss into the furcation;
Type 2. Vertical attachment loss into the furcation.
2 Fedi, P.F. [35] 1985
Glickman + Hamp classifications: Grades are the same as Glickman’s
classification (I–IV);
Grade II is subdivided into degrees I and II;
Degree I. Vertical bone loss 1–3 mm;
Degree II. Vertical bone loss > 3 mm, but not communicate
through-and-through.
3 Rosemberg, M.M. [36] 1986
Horizontal: Degree I: Probing < 4 mm; Degree II: Probing > 4 mm; Degree III:
Two or three furcations classified as degree II are found.
Vertical: Shallow: Slight lateral extension of an interradicular defect, from the
center of the trifurcation in a horizontal direction; Deep: Internal furcation
involvement but not penetrating the adjacent furcation.
4 Hou, G.L. et al. [37] 1998
Classification based on root trunk length and horizontal and vertical bone loss.
Types of root trunk:
• Type A: Furcation involving a cervical third of root length;
• Type B: Furcation involving a cervical third and two thirds of root length;
• Type C: Furcation involving a cervical two thirds of root length.
Classes of furcation:
• Class I: Horizontal loss of 3 mm;
• Class II: Horizontal loss > 3 mm;
• Class III: Horizontal “through-and-through” loss.
Subclasses by radiographic assessment of the periapical view:
• Sub-class ‘a’. Suprabony defect;
• Sub-class ‘b’. Infrabony defect.
2. Results
2.1. Study Characteristics
A total of ten studies were included in this systematic review after independent screening of titles
and abstracts from a pool of 153 articles retrieved from the search platforms. The systematic flow
chart of the study selection process is provided in Figure 1. Out of 21 eligible studies, 11 studies were
excluded with reasons provided in Table 2. The general information and the study characteristics of
the included studies are detailed in Table 3.
The general comparison was between a group that received APC as an adjunct to surgical
treatment (experimental group), and a group that received surgical treatment alone (control group).
Three different types of comparisons were assessed, based on the treatment type. Five studies reported
the comparison of open flap debridement (OFD) + APC versus OFD alone (Bajaj 2009 study evaluated
the adjunctive effects of two different types of APCs in the same study, compared to OFD alone as the
control group). Four studies reported the comparison of bone graft (BG) + APC versus BG alone, and
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only one study reported the comparison of guided tissue regeneration (GTR) + APC versus GTR alone.
The results of these studies were separated for types of platelet concentrate data to facilitate subgroup
meta-analysis for OFD + APC versus OFD comparison. However, it was impossible to undertake the
subgroup analysis for the other two comparisons due to the lack of enough studies for sub-grouping.
The risk of bias of all included studies is synthesized in Figure 2.
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Table 2. List of excluded studies.
Study & Year Reason for Exclusion
Mehta et al. 2018 [38] Use of Collagen Membrane along with DFDBA in control group
Wanikar et al. 2018 [39] Both Control and Experimental group use PRF
Kaur et al. 2018 [40] Both Control and Experimental group use PRF
Sharma et al. 2017 [41] Both Control and Experimental group use PRF
Asimuddin et al. 2017 [42] Comparison between use of PRF and Allograft + GTR
Salaria et al. 2016 [43] Case Report
Biswas et al. 2016 [44] Comparison between PRF and Bioactive Glass.
Pradeep et al. 2016 [45] Both Control and Experimental group uses PRF
Sandhu et al. 2015 [46] Case Report
Mellonig et al. 2009 [47] Histological assessment
Lekovic et al. 2003 [48] Comparison of PRP/BPBM/GTR versus OFD alone
PRF—platelet-rich fibrin, PRP—platelet-rich plasma, DFDBA—de-mineralized freeze-dried allograft,
BPBM—bovine porous bone mineral, GTR—guided tissue regeneration.
Table 3. Characteristics of included studies.
Study & Year StudyDesign RCT Type
Treatment
Comparison
N. Defects
Test/Control Age Range
Gender
M/F
Follow
Up
Kanoriya et al.
2017 [13] RCT Parallel OFD vs. OFD + PRF 26/26 30–50 (38) 36/36 9 m
Siddiqui et al.
2016 [49] RCT Parallel OFD vs. OFD + PRF 17/17 30–50 24/7 6 m
Bajaj et al.
2013 [11] RCT Parallel
OFD vs. OFD + PRP
OFD vs. OFD + PRF
27/27
27/27 39.4 22/20 9 m
Sharma et al.
2011 [17] RCT
Split
Mouth OFD vs. OFD + PRF 18/18 34.2 10/8 9 m
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Table 3. Cont.
Study & Year StudyDesign RCT Type
Treatment
Comparison
N. Defects
Test/Control Age Range
Gender
M/F
Follow
Up
Pradeep et al.
2009 [6] RCT
Split
Mouth OFD vs. OFD + PRP 20/20 42.8 10/10 6 m
Lohi et al.
2017 [14] RCT Parallel
BCCG + PRF vs.
BCCG alone 10/10
25–65
(43.05 + 10.73) 12/4 6 m
Lafzi et al.
2013 [15] RCT Parallel
ABG + PRGF vs.
ABG alone 15/15 NR NR 6 m
Mansouri et al.
2012 [50] RCT
Split
Mouth
BPBM + PRGF vs.
BPBM alone 7/7 44.7 + 11.2 4/3 6 m
Qiao et al.
2017 [16] RCT Parallel
BG + CGF vs. CGF
alone 15/16 NR 15/5 12 m
Jenabian et al.
2017 [12] RCT
Split
Mouth
GTR + PRGF vs.
GTR alone 8/8 NR NR 6 m
RCT—randomized clinical trial, OFD—open flap debridement, PRF—platelet-rich fibrin, PRP—platelet-rich plasma,
BCCG—bioactive ceramic composite granules, ABG—autogenous bone graft, BG—bone graft, GTR—guided
tissue regeneration.Int. J. Mol. Sci. 2019, 20, x 6 of 17 
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2.2. Meta-Analysis of Primary Outcomes
2.2.1. Probing Pocket Depth (PPD)
APC + OFD vs. OFD Alone (Figure 3)
The forest plot of the included studies evaluating the change in PPD shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.59, 95% CI 1.38, 1.80).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.46, 95% CI 1.22, 1.70)
and PRP (p < 0.001, mean difference 2.09, 95% CI 1.62, 2.55).Int. J. Mol. Sci. 2019, 20, x 7 of 17 
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15
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Heterogeneity: Chi² = 4.84, df = 3 (P = 0.18); I² = 38%
Test for overall effect: Z = 13.30 (P < 0.00001)
1.2.2 Platelet Rich Plasma
Bajaj  2013 b
Pradeep 2009
Subtotal (95% CI)
Heterogeneity: Chi² = 4.44, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 7.49 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 12.32, df = 5 (P = 0.03); I² = 59%
Test for overall effect: Z = 15.17 (P < 0.00001)
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Mean
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Total
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23
24
18
15
80
23
20
43
123
Weight
15.0%
33.5%
26.7%
9.7%
85.0%
11.6%
3.4%
15.0%
100.0%
IV, Fixed, 95% CI
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1.06 [0.78, 1.34]
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1.18 [1.01, 1.36]
1.34 [0.87, 1.81]
2.40 [1.53, 3.27]
1.58 [1.17, 2.00]
1.24 [1.08, 1.40]
APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours OFD Favours APC + OFD
r l s
APC + BG vs. BG Alone (Figure 4)
The forest plot of the included studies evaluating the change in PPD in using APC in adjunct
with BG favors the use of BG alone; however, the result is not statistically significant (p = 0.26, mean
difference −0.08, 95% CI −0.22, 0.06).
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Figure 4. Forest plot showing the effect on probing pocket depth for comparison of APC + BG versus
BG alone at end of all-follow-up (6–12 m).
2.2.2. Vertical Clinical Attachment Level (VCAL)
APC + OFD vs. OFD Alone (Figure 5)
The forest plot of the included studies evaluating the change in VCAL shows evidence of an
advantage of using APC in adjunct o OFD (p < 0.001, mean difference 1.24, 95% CI 1.08, 1.40).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.18, 95% CI .01, 1.36)
and PRP (p < 0.001, mean diffe enc 1.58, 95% CI 1.17, 2. ).
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Figure 5. Forest plot showing the effect on vertical clinical attachment level for comparison of APC +
OFD versus OFD alone at end of all-follow-up (6–12 m).
APC + BG vs. BG Alone (Figure 6)
The forest plot of the included studies evaluating the change in VCAL in using APC in adjunct
with BG is favorable; however, the result is not statistically significant (p = 0.62, mean difference 0.06,
95% CI −0.18, 0.30).
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Figure 6. Forest plot showing the effect on vertical clinical attachment level for comparison of APC +
BG versus BG alone at end of all-follow-up (6–12 m).
2.2.3. Horizontal Clinical Attachment Level (HCAL)
APC + OFD vs. OFD Alone (Figure 7)
The forest plot of the included studies evaluating the change in HCAL shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.01, 95% CI 0.89, 1.12).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 0.93, 95% CI 0.80, 1.06)
and PRP (p < 0.001, mean difference 1.50, 95% CI 1.18, 1.83).
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Figure 7. Forest plot showing the effect o i t l li ical attachment level for comparison of APC
+ OFD versus OFD alone at end of all-follow-up (6 ).
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APC + BG vs. BG Alone (Figure 8)
The forest plot of the included studies evaluating the change in HCAL shows evidence of an
advantage of using APC in adjunct with BG (p < 0.001, mean difference 0.74, 95% CI 0.54, 0.94).Int. J. Mol. Sci. 2019, 20, x 9 of 17 
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Figure 8. Forest plot showing the effect on horizontal clinical attachment level for comparison of APC
+ BG versus BG alone at end of all-follow-up (6–12 m).
2.2.4. Vertical Furcation Depth (VFD)
APC + OFD vs. OFD Alone (Figure 9)
The forest plot of the included studies evaluating the change in VFD shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.60, 95% CI 1.53, 1.68).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.65, 95% CI 1.57, 1.74)
and PRP (p < 0.001, mean difference 1.38, 95% CI 1.21, 1.56).
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Figure 10. Forest plot showing the effect on vertical furcation depth for comparison of APC + BG
versus BG alone at end of all-follow-up (6–12 m).
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2.2.5. Horizontal Furcation Depth (HFD)
APC + OFD vs. OFD Alone (Figure 11)
The forest plot of the included studies evaluating the change in HFD shows evidence of
an advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.13, 95% CI 0.85,1.41).
No subgroup analysis was carried out for this outcome due to the lack of enough studies.
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APC + BG vs. BG Alone (Figure 12)
The forest plot of the included studies evaluating the change in VFD shows evidence of
an advantage of using APC in adjunct with BG (p = 0.02, mean difference 0.17, 95% CI 0.02, 0.31).
Int. J. Mol. Sci. 2019, 20, x 10 of 17 
 
2.2.5. Horizontal Furcation Depth (HFD) 
APC + OFD vs. OFD Alone (Figure 11) 
The forest plot of the included studies evaluating the change in HFD shows evidence of an 
advantage of using APC in adj nct to OFD (p < 0.001, mean difference 1.13, 95% CI 0.85,1.41). No 
subgroup nalysis was carried out for this outcome due to the l ck o  nough studies. 
 
Figure 11. Forest plot showing the effect on horizontal furcation length for comparison of APC + OFD 
versus OFD alone at end of all-follow-up (6–12 m). 
   .  l  ( i r  ) 
 f r t plot of the included studies evaluating the change in VFD shows evidenc  of an 
dvant ge of using APC in adjunct with BG (p = 0.02, mean difference 0.17, 95% CI 0.02, 0.31). 
 
Figure 12. Forest plot showing the effect on horizontal furcation length for comparison of APC + BG 
versus BG alone at end of all-follow-up (6–12 m). 
3. Discussion 
The use of platelet concentrates to promote periodontal regeneration has gained popularity in 
the last 10 years, as demonstrated by the increasing number of evidence-based ra domized studies 
and systematic reviews [19,51,52]. A recent Cochrane systematic review [53] investigated the effect 
of APC for the surgical treatment of infrabony defects, reporting positive effects when APC is used 
in combination with OFD, OFD + BG, but n t with GTR and enamel matrix derivative. The latter two 
treat ents have a predictable and well-documented efficacy, and they are since long considered the 
gold standard for periodontal defects, s  it ca  be difficult for any adjunctive therapy to further 
enhance the clinical outcomes. Evidence-based studies on the efficacy of APC for the regeneration 
therapy of furcation defects are relatively scarce as compared to infrab ny defects. Our systematic 
review published i  2011 investigated the effects of APC on infrabony defects, gingival recessions 
and furcation defects but found only two studies on the latter topic, both using platelet-rich plasma 
[19]. The present study is the first comprehensive systematic review that was aimed at exploring and 
comparing the effect of various APCs for enhancing furcation treatment. It was designed accordi g 
t  a standard protocol, aimed at selecting only the best evidence studies, so as to provi e the most 
reliable results. Only one of the ten included studies was judged at high risk of bias [50], while seven 
had a low risk, testifyi g to the good level of the evidence of this review. The results, derived from 
the analysis of different clinical outcome variables, suggested t at the use of APC may be beneficial 
for improving the regeneration of furcation defects, when associated with OFD, in line with the above 
Study or Subgroup
Pra eep 2009
Sid iqui 2016
Total (95% CI)
Heterogeneity: Chi² = 0.37, df = 1 (P = 0.54); I² = 0%
T st f r ov rall effect: Z = 7.92 (P < 0.00001)
Mean
1.33
2.1
SD
0.93
.52
Total
20
15
35
Mean
0.09
1. 7
SD
0.48
. 6
Total
20
15
35
Weight
37.0%
63.
100.0%
IV, Fixed, 95% CI
1.24 [0.78, 1.70]
.06 [ . 1, .41]
1.13 [0.85, 1.41]
APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
OFD alone APC + OFD
Study or Subgroup
Lafzi 2013
Lohi 2017
Qiao 2017
Total (95% CI)
He erogeneity: Chi² = 5.48, df = 2 (P = 0.06); I² = 64%
Test for overall effect: Z = 2.29 (P = 0.02)
Mean
1
2
2.51
SD
0.174
0.756
2.18
Total
15
8
16
39
Mean
0.87
1.1
1.3
SD
0.226
0.876
2.47
Total
15
10
16
41
Weight
95.7%
3.5
0.8
100.0%
IV, Fixed, 95% CI
0.13 [-0.01, 0.27]
0.90 [0.15, 1.65]
1.21 [-0.40, 2.82]
0.17 [0.02, 0.31]
APC + BG BG alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
BG alone APC + BG
Figure 12. Forest plot showing the effect on horizontal furcation length for comparison of APC + BG
versus BG alone at end of all-follow-up (6–12 m).
3. Discussion
The use of platelet concentrates to promote periodontal regeneration has gained popularity in
the last 10 years, as demonstrated by the increasing number of evidence-based randomized studies
and systematic reviews [19,51,52]. A recent Cochrane systematic review [53] investigated the effect
of APC for the surgical treatment of infrabony defects, reporting positive effects when APC is used
in combination with OFD, OFD + BG, but not with GTR and enamel matrix derivative. The latter
two treatments have a predictable and well-documented efficacy, and they are since long considered
the gold standard for periodontal defects, so it can be difficult for any adjunctive therapy to further
enhance the clinical outcomes. Evidence-based studies on the efficacy of APC for the regeneration
therapy of furcation defects are relatively scarce as compared to infrabony defects. Our systematic
review published in 2011 investigated the effects of APC on infrabony defects, gingival recessions and
furcation defects but found only two studies on the latter topic, both using platelet-rich plasma [19].
The present study is the first comprehensive systematic review that was aimed at exploring and
comparing the effect of various APCs for enhancing furcation treatment. It was designed according
to a standard protocol, aimed at selecting only the best evidence studies, so as to provide the most
reliable results. Only one of the ten included studies was judged at high risk of bias [50], while seven
had a low risk, testifying to the good level of the evidence of this review. The results, derived from the
analysis of different clinical outcome variables, suggested that the use of APC may be beneficial for
improving the regeneration of furcation defects, when associated with OFD, in line with the above
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findings regarding infrabony defects. Further, it may be noted that APC in adjunct to OFD + BG also
showed significant improvement in HCAL and HFL. Since only one RCT evaluated the adjunctive
effect of APC when using GTR for grade II furcation defects, no meta-analysis was feasible. The results
of this study, suggested that the adjunct of APC produced no significant advantage as compared to
GTR alone, in line with previous findings for infrabony defects.
This review has some strengths and limitations. In recent years, there has been fierce competition
among companies producing different types of platelet concentrates, all claiming that their product
was superior to the others. This also introduced a number of different protocols for the preparation
of APC. Indeed, very few studies comparing different types of APC have been performed in the
periodontal field (as well as in other fields), so that it seems difficult to indicate if there is really
a superiority of some APCs over the others for specific conditions. In the present review, we were
able to perform a meta-analysis with subgroups, keeping separate different APC (PRP and PRF), only
in the group considering OFD alone. The outcomes using different APC was very similar as can be
seen in Figures 3–6 This can be considered a strong point of the present review. However, the precise
difference in effects between different APC cannot be estimated, due to a lack of direct comparisons.
The same subgroup analysis could not be performed in the OFD + BG group, due to heterogeneity
among studies in the type of APC used, and the insufficient number of studies using the same type
of APC. Indeed, also when different studies use the same type of APC, this does not necessarily
represent a warranty of homogeneity in the protocols. For example, over 20 different types of devices
producing PRP are currently available on the market, and at least five different companies produce
centrifuges for PRF [54]. A recent in vitro study compared the characteristics of PRF obtained using
four different centrifuge systems [55]. This study found that, even though in all cases a leukocyte- and
platelet-rich fibrin is obtained after centrifugation, the centrifuge characteristics and centrifugation
protocols significantly impact the cell composition and distribution, the growth factors release pattern
and the fibrin architecture of the final products. So, when PRF is used in different studies, one cannot
be sure to refer to a product with the same features, unless the same centrifuge system is used. In spite
of the above limitations, caused by lack of homogeneity in study protocols, it can be noted that all
studies investigating the effect of APC as an adjunct to OFD alone, consistently reported a beneficial
effect. The latter can be considered a strength point evidenced by this review.
In addition to the regenerative properties, platelet concentrates have also been demonstrated to
carry further advantages in the postsurgical healing period. Evidence-based studies in different oral
surgery procedures have reported that the adjunctive use of APC is associated with an improvement
of patients’ quality of life and pain reduction in the post-surgical period [56,57] Unfortunately, such
effects were not consistently addressed in the studies included in the present review.
Finally, though specific clinical studies have not been performed so far, there is consistent
preclinical evidence that APCs have an antimicrobial effect against a number of species commonly
found in the oral cavity, which suggest they may potentially represent a beneficial tool for the control of
postsurgical infection [58,59]. Indications for future research: There is a huge demand for conducting
more evidence-based comparative studies with wide sample size (among different APC and grafting
materials and versus other biological agents), to investigate patients’ quality of life, to treat various
grades of furcation, in order to verify the actual beneficial effects of use of APC as adjunct with wide
variety of regenerative strategies.
4. Material and Methods
This systematic review and meta-analysis were carried out based on preferred reporting items for
systematic reviews and meta-analysis (PRISMA) guidelines. The protocol of this systematic review
was registered on the international prospective register of systematic reviews (PROSPERO) with
registration number CRD42019100015.
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4.1. Research Question
What is the effectiveness of autologous platelet concentrates used as an adjunct to different
types of surgical techniques for the treatment of furcation defects, compared to the same surgical
techniques alone?
4.2. Search Strategy
A systematic digitalized search was carried out in the following electronic databases: MEDLINE,
SCOPUS, CENTRAL (Cochrane Central Register of Controlled Trials), and EMBASE, using a series of
search terms combined with the Boolean Operators “AND”, “OR”, and “NOT”. The following search
string was developed with the combination of relevant keywords: “(((Furcation Defects) OR Furcation
Involvement)) AND (((((((Platelet Concentrates) OR Platelet-rich plasma) OR Platelet-rich fibrin) OR
Growth factors) OR PRP) OR L-PRF) OR CGF)”. The last electronic search was carried out in October
2018. In addition, a hand search was performed in the following dental journals: British Dental Journal,
British Journal of Oral and Maxillofacial Surgery, Clinical Implant Dentistry and Related Research,
Clinical Oral Implants Research, Clinical Oral Investigations, European Journal of Oral Implantology,
European Journal of Oral Sciences, Implant Dentistry, International Journal of Oral and Maxillofacial
Implants, International Journal of Oral and Maxillofacial Surgery, International Journal of Periodontics
and Restorative Dentistry, Journal of Clinical Periodontology, Journal of Dental Research, Journal of
Dentistry, Journal of Implantology, Journal of Maxillofacial and Oral Surgery, Journal of Oral and
Maxillofacial Surgery, Journal of Periodontal Research, Journal of Periodontology, and Oral Surgery,
Oral Medicine, Oral Pathology, Oral Radiology. The reference citations of the eligible studies and other
systematic reviews were also searched for possible additional eligible studies. Finally, the online trial
registries were also searched for any ongoing studies: US National Institutes of Health Ongoing Trials
Register ClinicalTrials.gov (clinicaltrials.gov; searched 20 October 2018); World Health Organization
International Clinical Trials Registry Platform (apps.who.int/trialsearch; searched 20 October 2018).
No language restrictions were applied.
4.3. Inclusion Criteria
The criteria for the articles to be included in this present systematic review were as follows:
• Randomized clinical trials (RCT), either of a parallel group or of a split-mouth design;
• Presence of at least one experimental group in which APCs were clinically applied as an adjunct
to surgical procedures alone or in combination with bone grafting materials or GTR procedures
for the therapy of furcation defects;
• Presence of an appropriate control group, in which the same therapeutic procedures as those
employed in at least one experimental group were clinically applied for the treatment of furcation
defects, without the adjunctive effect of APCs;
• Patients included in the RCT should present with maxillary/mandibular Grade 2 or 3
furcation defects;
• Patients included in the RCT should have no systemic diseases nor taking medications that could
potentially influence the outcome of periodontal therapy;
• The follow-up period had to be at least 6 months.
4.4. Selection of Studies
Following the electronic search in all the respective databases, the records were imported into
EndNote 13 software (EndNoteX3; Thomas Reuters, New York, NY, USA) and the duplicates were
sorted to be removed from the pool of titles. A total of 153 titles and abstracts (if available) were
independently screened by two reviewers (MDF, SP) to exclude all articles clearly not meeting the
inclusion criteria. Of all the eligible articles, full texts were obtained and were thoroughly assessed.
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Only articles fulfilling the inclusion criteria were considered. In cases of disagreement between the two
reviewers, a third reviewer (LF) was consulted. Detailed reasons were stated for all excluded studies.
4.5. Data Extraction and Management
The relevant data of the included studies were extracted using an Excel spreadsheet (Microsoft,
Radmond, WA, USA). Data were independently extracted by two review authors (MDF, FG) and
recorded on predetermined spreadsheets. In case of missing or unclear information, the authors of the
included studies were contacted by email for providing clarification or missing information.
The following data were recorded for each included report:
• Patients’ demographic characteristics
• Study design and sample size
• Type of platelet concentrate used (PRP, PRF, PRGF, CGF)
• Follow up duration
• source of funding and study setting
• Outcome variables, relative to baseline and post-operative defect characteristics (probing pocket
depth (PPD), horizontal and vertical clinical attachment loss (HCAL, VCAL), horizontal and
vertical furcation depth (HFD, VFD)
4.6. Risk of Bias Assessment
Risk of Bias was assessed by two independent reviewers (ACD, AS) for all the included clinical
trials and the discrepancies were resolved by discussion and in consent with a third reviewer (MK). The
domains of the study were graded under high, unclear or low risk, based on the following categories:
Selection bias (random sequence generation and allocation concealment), performance bias (blinding),
detection bias (assessor blinding), attrition bias (incomplete outcome data), reporting bias (selective
reporting), sample size calculation and number of surgeons involved. Based on the domains, the
studies categorized as low risk of bias if all domains were at low risk; high risk of bias if two or more
domains were at high risk; or medium risk of bias if one domain were at unclear or high risk.
4.7. Data Synthesis
Data of the various outcomes were extracted from each included study. Parallel group and
split-mouth studies were combined in the meta-analysis of treatment effects. For all the outcomes,
mean differences and 95% confidence interval (CI) were used to summarize the results for each
included study. The meta-analysis was performed using Review Manager 5.3 software (RevMan 5.3,
Version 5.3.5 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) using
the fixed or random effects models, as appropriate. Fixed effects meta-analysis was used when the
heterogeneity was small (i2 < 60%, p > 0.05). When the heterogeneity was large (i2 > 60%, p < 0.05),
a random-effects model analysis was undertaken.
5. Conclusions
In conclusion, the evidence available in the literature for the beneficial effects of platelet
concentrates in periodontal furcation defects has been increasing in recent years. Platelet-rich plasma
and platelet-rich fibrin may be advantageously used as an adjunct to open flap debridement alone
and additional grafting procedures, while there is no evidence of an effect of APC when used in
combination with GTR, for the treatment of furcation defects.
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Abbreviations
APCs Autologous platelet concentrates
PPD Probing pocket depth
HCAL Horizontal clinical attachment loss
VCAL Vertical clinical attachment loss
HFD Horizontal furcation depth
VFD Vertical furcation depth
GTR Guided tissue regeneration
rhBMP2 Recombinant human bone morphogenetic protein-2
rhPDGF Recombinant human platelet-derived growth factor
TGF-β Transforming growth factor beta
PRP Platelet-rich plasma
PRF Platelet-rich fibrin
PRGF Plasma rich in growth factors
CGF Concentrated growth factors
PRISMA Preferred reporting items for systematic reviews and meta-analysis
RCT Randomized clinical trials
CI Confidence interval
OFD Open flap debridement
BG Bone graft
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